Risk Factors of BK Viral Hemorrhagic Cystitis in Allogenic Hematopoietic Stem Cell Transplantation

2021 ◽  
Author(s):  
Eléonore Kaphan ◽  
Raphaele Germi ◽  
Sébastien Bailly ◽  
Claude‐Eric Bulabois ◽  
Martin Carré ◽  
...  
Keyword(s):  
Risk Factors ◽  
Stem Cell ◽  
Hematopoietic Stem Cell Transplantation ◽  
Stem Cell Transplantation ◽  
Cell Transplantation ◽  
Hematopoietic Stem Cell ◽  
Hemorrhagic Cystitis ◽  
Hematopoietic Stem

BK Virus-Associated Hemorrhagic Cystitis After Allogeneic Hematopoietic Stem Cell Transplantation in the Pediatric Population

2016 ◽  
Vol 34 (1) ◽  
pp. 13-19 ◽  
Author(s):  
Pablo Pérez-Huertas ◽  
Margarita Cueto-Sola ◽  
Paloma Escobar-Cava ◽  
José María Fernández-Navarro ◽  
Carmela Borrell-García ◽  
...  
Keyword(s):  
Risk Factors ◽  
Stem Cell ◽  
Hematopoietic Stem Cell Transplantation ◽  
Stem Cell Transplantation ◽  
Cell Transplantation ◽  
Hematopoietic Stem Cell ◽  
Pediatric Population ◽  
Hemorrhagic Cystitis ◽  
Bk Virus ◽  
Hematopoietic Stem

Objective: To study the incidence, risk factors, and treatment of hemorrhagic cystitis secondary to BK-virus reactivation (HC-BKV) after allogeneic hematopoietic stem cell transplantation (allo-HSCT) in the pediatric population. Methods: Case-control study in which all pediatric patients (0-18 years) who underwent allo-HSCT from September 2009 to January 2014 were followed. Results: Twenty-nine patients underwent an allo-HSCT. The median age was 9 years (range = 6 months to 15 years), 61% male. The primary diagnosis was acute lymphoblastic leukemia (72.4%). Six (20.7%) developed HC-BKV. In a multivariate analysis of risk factors, it was observed that the reactivation of BK virus was associated with age more than 10 years ( P = .098) and those with positive serology for Epstein-Barr virus ( P = .06). Five of the 6 patients with HC-BKV received cidofovir (CDV) at doses of 3 to 5 mg/kg/week. The treatment lasted a median of 3 cycles (range = 2-5). One of the patients (20%) developed nephrotoxicity. Of the 5 patients treated with CDV, 3 (60%) had a complete response, 1 (20%) partial response, and 1 (20%) no response. Conclusion: We conclude that HC-BKV is a frequent complication after allo-HSCT. CDV therapy can be effective but controlled clinical trials are needed.

scholarly journals Clinical Analysis of Hemorrhagic Cystitis after Allogeneic Hematopoietic Stem Cell Transplantation

Blood ◽  
2020 ◽  
Vol 136 (Supplement 1) ◽  
pp. 38-38
Author(s):  
Biao Shen ◽  
Aiming Pang ◽  
Erlie Jiang ◽  
Sizhou Feng ◽  
Ming-Zhe Han
Keyword(s):  
Risk Factors ◽  
Stem Cell ◽  
Hematopoietic Stem Cell Transplantation ◽  
Stem Cell Transplantation ◽  
Cell Transplantation ◽  
Hematopoietic Stem Cell ◽  
Hemorrhagic Cystitis ◽  
Hla Matching ◽  
Hematopoietic Stem ◽  
Cd34 Cells

Objective: To analyze the risk factors and survival of the patients with hemorrhagic cystitis (HC) after allogeneic hematopoietic stem cell transplantation (HSCT).Methods: Propensity score Matching was conducted for HC patients among 523 patients who received HSCT in Hematopoietic Stem Cell Transplantation Center, Institute of Hematology & Blood Disease Hospital, Chinese Academy of Medical Sciences from August 2016 to August 2019. Non-HC patients were selected with a ratio of 1:2 (HC: non-HC) and then statistically analyzed with SPSS 22.0. Results:130 HC patients and 233 non-HC patients were included in the study. There were HC of grade I-II in 114/130 cases(87.69%) and of grade III-IV in 16/130 (12.31%), The median time of onset was 33 days after HSCT(range 3-339 days).Univariate analysis indicated that HC occurrence were associated with the source of stem cells, infusion CD34+ cells count, morphologic remission before transplantation, HLA matching, urinary BK virus load and the drug of Bu in conditioning regimens. Multiple regression analysis showed that morphologic remission before transplantation, HLA matching and infusion CD34+ cells count were associated with HC. K-M survival analysis showed that the 1-year survival rate of HC and non-HC was 91.8% vs 86.3%, and the 2-year survival rate was 52.5% vs 50.6%, respectively, showing no statistical difference. ROC curve showed that when the level of BKV is higher than 5×108 copies /ml, the risk of HC would increase. Conclusion: HC was associated with morphologic remission before transplantation, HLA matching and infusion CD34+ cells count. There was no significant difference in survival between HC and Non-HC groups. the level of urinary BKV load higher than 5×108 copies /ml may cause hemorrhagic cystitis symptoms. Key words: hemorrhagic cystitis; Allogeneic hematopoietic stem cell transplantation; Risk factors; Prognosis Disclosures No relevant conflicts of interest to declare.

P1825ANALYSIS OF LATE RENAL COMPLICATIONS AND RISK FACTORS IN CHILDREN WITH HEMATOPOIETIC STEM CELL TRANSPLANTATION

2020 ◽  
Vol 35 (Supplement_3) ◽  
Author(s):  
Anar Gurbanov ◽  
Bora Gülhan ◽  
Barış Kuşkonmaz ◽  
Fatma Visal Okur ◽  
Duygu Uçkan Çetinkaya ◽  
...  
Keyword(s):  
Risk Factors ◽  
Blood Pressure ◽  
Stem Cell ◽  
Hematopoietic Stem Cell Transplantation ◽  
Stem Cell Transplantation ◽  
Cell Transplantation ◽  
Hematopoietic Stem Cell ◽  
Hematopoietic Stem ◽  
Renal Complications

Abstract Background and Aims The aim of the study is to investigate the incidence and risk factors of hypertension (HT) and chronic kidney disease (CKD) in patients who had hematopoietic stem cell transplantation (HSCT) during their childhood. Method Patients who had HSCT between January 2010-2019 with a minimum follow-up period of 6 months were included in the study. Data regarding renal complications were collected from the medical records of the patients. Guidelines of European Society of Hypertension (ESH) and American Academy of Pediatrics (APA) were used for the evaluation of hypertension. 24-hr ambulatory blood pressure monitoring (ABPM) was performed in children older than 5 years of age (68 patients). Ambulatory hypertension is diagnosed when systolic and/or diastolic blood pressure (BP) load is higher than 25%. Ambulatory prehypertension is diagnosed when mean systolic and/or diastolic BP is less than 95th percentile with systolic and/or diastolic BP load higher than 25%. Results A total of 72 patients (41 males and 31 females) were included in the study. The mean age of the patients at last visit was 10.8±4 years. ABPM revealed ambulatory HT in 6 patients (8.8%) and ambulatory prehypertension in 12 patients (17.6%). Office BP revealed HT in 3 patients (4.2%) and increased BP in four patients (5.6%) according to APA guideline (2017). In cohort, 12 patients with normal office BP (according to APA guideline) had ambulatory prehypertension or hypertension with ABPM. Office BP revealed HT in 1 patient (1.4%) and high-normal BP in 3 patients (4.2%) according to ESH guideline. In cohort, 15 patients with normal office BP (according to ESH guideline) had ambulatory prehypertension or hypertension with ABPM (Table 1). After a mean follow-up period of 4.4±2.5 years, CKD developed in 8 patients (11.1%). Patients with chronic graft-versus-host disease, with HLA-mismatched HSCT and/or transplantation of peripheric or cord blood hematopoietic stem cells had increased risk of CKD (p=0.041, p=0.033 and p=0.002, respectively). Conclusion Patients with HSCT should be regularly followed for the development of HT and ABPM should be used on regular basis. Patients with risk factors should be closely monitored for the development of CKD.

Sign in / Sign up

Export Citation Format

Share Document